A

Adverum Biotechnologies
D

ADVM

3.95000
USD
-0.04
(-0.88%)
مغلق
حجم التداول
1,192
الربح لكل سهم
-6
العائد الربحي
-
P/E
-1
حجم السوق
82,169,729
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    B
    BMRN
    -0.525
    (-0.76%)
    68.215 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Adverum Biotechnologies

القطاع: Healthcare
الصناعة: Biotechnology
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.